Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) has reached a significant milestone in its partnership with Bayer AG, receiving a USD $1 million payment after Bayer approved its complete feasibility work plan and timetable. This payment, part of a non-dilutive Collaboration and Funding Agreement dated February 10, 2026, brings the total received to USD $1.35 million of the USD $2.35 million committed by Bayer. The funds will support ongoing feasibility work, including the completion of a FEL-3 study by Fluor Corporation once the pilot plant is operational.
The milestone follows successful laboratory production of 99.8% purity iodine using Voyageur's proprietary Mueller extraction process, which was validated by the company's Houston R&D team. This technical confirmation allowed Bayer to advance the program. The transportable pilot plant is nearing completion and is scheduled for field operation this fall, with Fluor providing engineering and project planning support.
Brent Willis, President and CEO of Voyageur, emphasized the importance of this achievement: "Achievement of this first milestone under our agreement with Bayer is an important step forward for Voyageur. It confirms that the feasibility work is advancing as planned and triggers the first major non-dilutive payment under the collaboration. This capital is expected to further accelerate our iodine supply strategy and move us closer to validating a reliable North American source of high-purity iodine for use in contrast media drugs."
The collaboration aims to establish a domestic source of high-purity iodine for Bayer's contrast media manufacturing, addressing supply chain vulnerabilities. The project proposes a 1,000 tonnes per year production capacity with a staged rollout, beginning at 200 tonnes per year. Voyageur may evaluate deploying additional units to expand capacity over time, with a central manufacturing facility producing USP-grade pharmaceutical iodine.
Subject to the success of the feasibility study, Bayer and Voyageur may negotiate a long-term offtake agreement. The non-dilutive funding supports feasibility work through 2026, reflecting technical progress toward a secure supply chain. The global contrast media market is estimated at approximately USD $7.06 billion, underscoring the strategic importance of this initiative.
Voyageur's vertically integrated strategy aims to reduce reliance on imported raw materials and lower operating costs for contrast agents. The company plans to leverage near-term opportunities from barium contrast sales and iodine sales under the Bayer collaboration, with longer-term potential from contrast drug manufacturing. Fluor's engineering support is progressing on schedule, with subsequent phases expected to take 4-5 months for FEL-2 and 7-9 months for FEL-3.
Mr. Willis added: "Voyageur is focused on building multiple potential revenue streams through a staged commercialization strategy. The Bayer collaboration, combined with technical support from Fluor, continues to strengthen the foundation for scalable domestic iodine production." The company will provide updates as the feasibility work progresses and additional milestones are achieved.
